Trial Profile
A Multi-center, Multiple-ascending Dose, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Safety, Tolerability and Pharmacokinetics of Gantenerumab Following Subcutaneous Injection in Japanese AD Patients
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Gantenerumab (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors Chugai Pharmaceutical
- 18 Sep 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 13 Aug 2012 New trial record